FDA decision: Iberdomide by BMS/Celgene (in 2026)
FDA decision on Iberdomide in 2026Economics
FDA decision: Iberdomide by BMS/Celgene (in 2026)
FDA decision on Iberdomide in 2026Economics
Kalshi Active 1 markets Mutually Exclusive·73¢ What will the FDA's decision be on Iberdomide by Celgene in 2026?·$0 Total Volume·-- Liquidity·-- OI
5mo·Jan 8, 2027
Track your prediction positions
Connect your Kalshi account to track your contracts, P&L, and settlements.
What will the FDA's decision be on Iberdomide by Celgene in 2026?+0.0% 24h
Yes 73%
No 27%
$0 Vol
No chart data available
If the FDA's decision on Iberdomide by BMS/Celgene in 2026 is a full approval or an accelerated approval, the market resolves to Yes.
Track Your Bets on Kalshi — and Everything Else
Create a free portfolio starting with your Kalshi positions, P&L & live odds. Then add crypto wallets, exchanges, DeFi & more — all in one place.
Polymarket
Kalshi
50+ Chains
40+ Exchanges
DeFi
NFTs
16K+ Tokens
100% free· Read-only· Encrypted